PHN-012 in Advanced Solid Tumors - Clinical Trial
What is the Purpose of this Study?
This study has two parts. In the first part, called Phase 1a, doctors will test different amounts of a medicine called PHN-012 to find the safest dose. In the second part, called Phase 1b, doctors will see how well PHN-012 works against cancer. The medicine will be given through an IV, which means it goes into a vein. You will get the medicine every 21 days until your cancer gets worse or you have to stop because of bad side effects.
People can join this study if they have certain types of cancer that have spread or are very advanced. These include cancer of the colon (colorectal adenocarcinoma), cancer of the lung (adenocarcinoma or squamous cell carcinoma), or cancer of the pancreas (pancreatic ductal adenocarcinoma). People with a mix of two lung cancer types, called adenosquamous carcinoma, can also join.
Who Can Participate in the Study?
To join this study, you must be 18 years or older and have already had at least one treatment for advanced disease. You can join if there are no other proven treatments left, if you cannot handle the side effects of standard treatments, or if you choose not to have standard treatment after learning about all your options.
What is Involved?
The study wants to find out if a medicine called PHN-012 is safe and if people can handle it well. It also wants to see how well PHN-012 works to fight advanced solid tumors, which are a type of cancer.
Study Details
